Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **innovative drug and pharmaceutical industry** in China, highlighting the recovery of PS and PB ratios in Hong Kong's creative sales companies, although they have not yet reached historical highs, indicating a period of recovery [1][2]. Core Insights and Arguments - **Global Competitiveness of Chinese Innovative Drugs**: China possesses advantages in population, domestic demand, manufacturing, supply chain, and rapidly improving innovation capabilities, which are driving Chinese assets to go global. High-quality early-stage products from China are in significant demand in the U.S. market, with leading companies gradually increasing their performance [1][3]. - **Valuation Trends**: The innovative drug sector's valuation is expected to first recover to previous PS levels and then potentially break new highs as more products are launched and clinical data is disclosed. The number of products is projected to increase, which will enhance company valuations [1][4]. - **Performance of Kangfang Biotech**: Kangfang Biotech's data presented at WCLC showed a p-value of 0.000332 and an HR value of 0.78, indicating significant improvement, especially in brain metastasis patients, which is a rare and meaningful finding [1][5]. - **International Conference Participation**: In 2025, over 70 Chinese studies were showcased at ASCO, with ongoing presentations at international conferences like WCLC and ESMO, indicating China's growing international influence in innovative drug development [1][6][8]. Additional Important Content - **Diverse Treatment Areas**: The innovative drug trend is not limited to oncology but also includes immunology, with upcoming data releases at various international conferences, showcasing significant progress in multiple therapeutic areas [1][8]. - **Future Growth Expectations**: The Chinese innovative drug industry is anticipated to continue significant growth in the coming years, with more new data and products expected as operational logic is refined. The collaboration models are diversifying, enhancing China's global pricing power and influence [1][9]. - **Catalysts for Market Impact**: The second half of 2025 is expected to bring several important catalysts for the Chinese innovative drug market, including potential approvals for new products from leading companies like Heng Rui and developments from companies like Innovent Biologics and BeiGene [1][10][11]. - **Heng Rui Pharmaceutical's Performance**: As a leading company, Heng Rui's performance in the first half of 2025 was outstanding, with a significant increase in the number of products contributing to sales, reflecting its strong position in global transactions [1][12]. - **Innovent Biologics' Growth**: Innovent Biologics reported significant revenue growth of 5.95 billion, a 50.6% year-on-year increase, indicating improved operational efficiency [1][13]. - **Kangfang Biotech's Platform Value**: Kangfang Biotech demonstrated strong performance with a 49.2% growth in product revenue, showcasing its platform's value and potential for new dual and multi-antibody assets [1][14]. - **Bai Jie Shen Zhou's Financial Performance**: Bai Jie Shen Zhou reported a 17.5% quarter-on-quarter revenue increase, exceeding expectations, with new data updates expected in the second half of the year [1][16]. Conclusion - The innovative drug industry in China is on a recovery trajectory, with strong growth potential driven by competitive advantages, increasing product launches, and expanding international presence. The upcoming catalysts and ongoing developments in various companies are expected to further enhance the industry's outlook.

Performance Forecast - The company expects a net loss attributable to shareholders of 200 million to 400 million yuan for the first half of 2025, compared to a profit of 973.64 million yuan in the same period last year [1][2] - The net profit after deducting non-recurring gains and losses is projected to be a loss of 100 million to 200 million yuan, down from a profit of 623.52 million yuan year-on-year [1][2] - Basic earnings per share are expected to be a loss of 0.1406 to 0.2813 yuan, compared to earnings of 0.6891 yuan per share in the previous year [1][2] Business Segments Printer Business - The sales volume of printers in the Xinchuang market has significantly increased, with a year-on-year growth of approximately 65% in the first half of the year [1] - The sales volume of A3 copiers increased by about 115% year-on-year, with a quarter-on-quarter growth of approximately 30% in the second quarter [1] Integrated Circuit Business - Revenue from non-consumable chips reached approximately 254 million yuan, a year-on-year increase of about 52% [2] - The total shipment of chips was 168 million units, with a quarter-on-quarter growth of about 34% [2] General Consumables Business - Revenue from general consumables decreased by approximately 61% year-on-year, while total sales volume remained flat [2] Asset Disposal Impact - The company completed the major asset sale on July 1, 2025, which has significantly impacted the net profit and net profit after deducting non-recurring gains and losses [2] - The final confirmation of the transaction amount may be adjusted, potentially affecting the performance forecast data [2]